BridgeBio Pharma (BBIO) Income from Non-Controlling Interests (2018 - 2026)

BridgeBio Pharma has disclosed Income from Non-Controlling Interests across 9 years of filings, most recently posting -$2.5 million for Q1 2026.

• Income from Non-Controlling Interests for Q1 2026 came in at -$2.5 million, down 14.91% year-over-year; the trailing twelve-month figure through Mar 2026 was -$8.3 million (up 5.6% YoY), and the FY2025 annual result was -$8.0 million, down 5.56% from the prior year.
• Income from Non-Controlling Interests came in at -$2.5 million for Q1 2026 at BridgeBio Pharma, down from -$1.8 million in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $7.3 million in Q2 2022 to a low of -$4.9 million in Q1 2022.
• The 5-year median for Income from Non-Controlling Interests is -$2.2 million (2024), against an average of -$1.9 million.
• Across the five-year window, Income from Non-Controlling Interests soared 227.44% in 2022 and slumped 138.43% in 2023, its largest moves.
• BridgeBio Pharma's Income from Non-Controlling Interests stood at -$3.0 million in 2022, then grew by 26.82% to -$2.2 million in 2023, then declined by 7.29% to -$2.3 million in 2024, then gained by 24.24% to -$1.8 million in 2025, then sank by 41.76% to -$2.5 million in 2026.
• The last three Income from Non-Controlling Interests figures came in at -$2.5 million (Q1 2026), -$1.8 million (Q4 2025), and -$2.2 million (Q3 2025), per Business Quant data.